Literature DB >> 16857816

"Oncogenic shock": explaining oncogene addiction through differential signal attenuation.

Sreenath V Sharma1, Michael A Fischbach, Daniel A Haber, Jeffrey Settleman.   

Abstract

"Oncogene addiction" describes the curious acquired dependence of tumor cells on an activated oncogene for their survival and/or proliferation, a phenomenon that has important implications for the success of targeted cancer therapies. However, the mechanisms explaining oncogene addiction remain elusive. We propose that "addiction" may be an illusion generated as a consequence of differential attenuation rates of prosurvival and proapoptotic signals emanating from an oncoprotein acutely following its inactivation. According to this model, which we call "oncogenic shock," prosurvival signals dissipate quickly on oncoprotein inactivation whereas proapoptotic signals linger sufficiently long to commit the cell to an apoptotic death. This mechanism may contribute to the rapid and dramatic clinical responses observed in some cancer patients treated with selective tyrosine kinase inhibitors and could yield additional drug targets that determine the balance of signaling outputs from activated oncoproteins.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16857816     DOI: 10.1158/1078-0432.CCR-06-0096

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  45 in total

Review 1.  Aurora kinase inhibitors as anticancer molecules.

Authors:  Hiroshi Katayama; Subrata Sen
Journal:  Biochim Biophys Acta       Date:  2010-09-20

2.  A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes.

Authors:  Sreenath V Sharma; Patrycja Gajowniczek; Inna P Way; Diana Y Lee; Jane Jiang; Yuki Yuza; Marie Classon; Daniel A Haber; Jeffrey Settleman
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

3.  c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle.

Authors:  H Wang; S Mannava; V Grachtchouk; D Zhuang; M S Soengas; A V Gudkov; E V Prochownik; M A Nikiforov
Journal:  Oncogene       Date:  2007-10-01       Impact factor: 9.867

4.  Proteomic profiling identified multiple short-lived members of the central proteome as the direct targets of the addicted oncogenes in cancer cells.

Authors:  Tonggang Qi; Wei Zhang; Yun Luan; Feng Kong; Dawei Xu; Guanghui Cheng; Yunshan Wang
Journal:  Mol Cell Proteomics       Date:  2013-10-08       Impact factor: 5.911

5.  KRAS and HRAS mutations confer resistance to MET targeting in preclinical models of MET-expressing tumor cells.

Authors:  Dominic Leiser; Michaela Medová; Kei Mikami; Lluís Nisa; Deborah Stroka; Andree Blaukat; Friedhelm Bladt; Daniel M Aebersold; Yitzhak Zimmer
Journal:  Mol Oncol       Date:  2015-04-14       Impact factor: 6.603

Review 6.  Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh.

Authors:  Joel W Neal; Lecia V Sequist
Journal:  Curr Treat Options Oncol       Date:  2010-06

7.  RAS oncogene suppression induces apoptosis followed by more differentiated and less myelosuppressive disease upon relapse of acute myeloid leukemia.

Authors:  Won-Il Kim; Ilze Matise; Miechaleen D Diers; David A Largaespada
Journal:  Blood       Date:  2008-10-24       Impact factor: 22.113

8.  Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics.

Authors:  Jason A Wilken; Kristy T Webster; Nita J Maihle
Journal:  J Ovarian Res       Date:  2010-03-27       Impact factor: 4.234

9.  Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor.

Authors:  Matthew R Janes; Jose J Limon; Lomon So; Jing Chen; Raymond J Lim; Melissa A Chavez; Collin Vu; Michael B Lilly; Sharmila Mallya; S Tiong Ong; Marina Konopleva; Michael B Martin; Pingda Ren; Yi Liu; Christian Rommel; David A Fruman
Journal:  Nat Med       Date:  2010-01-13       Impact factor: 53.440

Review 10.  Factors underlying sensitivity of cancers to small-molecule kinase inhibitors.

Authors:  Pasi A Jänne; Nathanael Gray; Jeff Settleman
Journal:  Nat Rev Drug Discov       Date:  2009-07-24       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.